Lakefront Biotherapeutics NV（LKFT）资讯与事件LKFTLakefront Biotherapeutics NV

Lakefront Biotherapeutics Sells Cell Therapy Pipeline to Armed Cell Therapeutics

Lakefront Biotherapeutics announced that it has completed the sale of its early-stage cell therapy pipeline to Armed Cell Therapeutics BV, a Belgium-based biotechnology company developing next-generation armed CAR-T therapies for cancer and formed by experienced executives Paul Stoffels, John Mellors and Peter Verhaeghe. The preclinical program is based on technology originated from, and research undertaken by AboundBio, which was acquired by Lakefront NV in 2022. The terms of the agreement include an upfront payment of EUR 8M and the potential for up to $230M in milestone payments and a low-single-digit royalty to Lakefront. The transferred preclinical assets comprise multi-targeting and armed CAR-T constructs designed to improve the potency and persistence of CAR-Ts and prevent cancer treatment resistance in hematological and solid tumors of high unmet need. Armed Cell Therapeutics will independently advance these programs. Lakefront previously announced its intention to wind down its cell therapy activities following a comprehensive review of strategic alternatives. This process is substantially complete.

Lakefront Biotherapeutic Receives FDA Orphan Drug Designation

Lakefront Biotherapeutic (LKFT) announced that the FDA has granted orphan drug designation to gamgertamig for the treatment of pemphigus. Gamgertamig was previously granted both Fast Track and Orphan Drug Designation by the FDA for the treatment of autoimmune hemolytic anemia and immune thrombocytopenia. Gamgertamig is being developed by Lakefront in collaboration with Gilead (GILD). Ongoing clinical trials in autoimmune diseases are actively enrolling, and expansion of the clinical trials program is anticipated in 2027.